Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 1, January, p. 57–61

doi: 10.17219/acem/65860

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Clinical and immunological characteristics of Polish patients with systemic lupus erythematosus

Martyna Tomczyk-Socha1,B,C,D,E, Hanna Sikorska-Szaflik2,B,C,D,E, Marek Frankowski3,B,C,D, Karolina Andrzejewska3,B,C,D, Agnieszka Odziomek4,B,C,D, Magdalena Szmyrka3,A,B,E,F

1 Department and Clinic of Ophthalmology, Wroclaw Medical University, Poland

2 1st Department and Clinic of Pediatrics, Allergology and Cardiology, Wroclaw Medical University, Poland

3 Department and Clinic of Rheumatology and Internal Medicine, Wroclaw Medical University, Poland

4 Department of Dermatology, Regional Specialized Hospital, Wrocław, Poland


Background. Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with varied clinical manifestations, which creates difficulties and delays in establishing a diagnosis.
Objectives. The aim of this study was to evaluate the prevalence and nature of the clinical symptoms of SLE, both at the onset of the disease and in its further course. An attempt to assess the immunological characteristics of the patients and to analyze autoantibodies variability over time was also made.
Material and Methods. This retrospective study included 71 Caucasian patients, 63 women and 8 men, meeting the criteria for diagnosis of SLE according to ACR.
Results. The ratio of women to men was approximately 7.9:1. The average age of the onset of SLE was 31.5 years. The average time from the onset of symptoms to diagnosis was 5 years. The most common first manifestation of SLE were joint and muscles symptoms – 71.8%, skin lesions – 69.0%, fever – 57.7%. The main symptoms in the further course of the disease were neurological disorders – 69.0%, joint and muscle changes – 67.7%, and general symptoms – 59.2%. There was an increase in the incidence of renal involvement and neurological symptoms throughout the disease course. The most commonly detected antibodies were anti-dsDNA – 47.9%, anti-Ro/SSA – 40.8%, anti-nucleosomal antibodies – 29.6%, and lupus anticoagulant – 22.5%. A panel of antibodies typically did not change.
Conclusion. There is no typical clinical picture of SLE, the population suffering from this disease is very various. Therefore, early and accurate diagnosis can be a big challenge for any clinician, which justifies the need for this type of study to better characterize the disease.

Key words

systemic lupus erythematosus, SLE, course of SLE, onset of SLE

References (17)

  1. Williams AE, Crofts G, Teh LS. “Focus on feet” – The effects of systemic lupus erythematosus: A narrative review of the literature. Lupus. 2013;22(10):1017–1023.
  2. Ahmadpoor P, Dalili N, Rostami M. An update on pathogenesis of systemic lupus erythematosus. Iran J Kidney Dis. 2014;8(3):171–184.
  3. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–1277.
  4. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
  5. Cervera R, Khamashta MA, Hughes GRV. The Euro-Lupus project: Epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009;18:869–874.
  6. Majdan M. Toczeń rumieniowaty układowy. Reumatologia. 2012;50(2):103–110.
  7. Petri M. The effect of race on the presentation and course of SLE in the United States. Arthritis Rheum. 1997;40(Suppl):162.
  8. Alarcón GS, McGwin Jr G, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002;11:95–101.
  9. Wang F, Wang CL, Tan CT, Manivasagar M. Systemic lupus erythematosus in Malaysia: A study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups. Lupus. 1997;6:248–253.
  10. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58:556–562.
  11. Dung NT, Loan HT, Nielsen S, Zak M, Petersen FK. Juvenile systemic lupus erythematosus onset patterns in Vietnamese children: A descriptive study of 45 children. Pediatric Rheumatology Online J. 2012;10:38.
  12. Costallat LT, Coimbra AM. Systemic lupus erythematosus: Clinical and laboratory aspects related to age at disease onset. Clin Exp Rheumatol. 1994;12(6):603–607.
  13. Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: Clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053–1058.
  14. Hajduk A, Smoleńska Ż, Nowicka-Sauer K, et al. Neuropsychiatric syndromes in systemic lupus erythematosus patients. Reumatologia. 2012;50(6):493–500.
  15. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology. 2001;57(3):496–500.
  16. Fiedorowicz-Fabrycy I, Brzosko M. Diagnostics of neuropsychiatric complications in vascular diseases in the course of systemic connective tissue diseases. Reumatologia. 2005;43:369–372.
  17. Palagini L, Mosca M, Tani C, Gemignani A, Mauri M, Bombardieri S. Depression and systemic lupus erythematosus: A systematic review. Lupus. 2013;22(5):409–416.